Selecta Biosciences Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $5.25M Miss $11.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
Selecta Biosciences (NASDAQ:SELB) reported Q2 earnings per share of $(0.07), beating the analyst consensus estimate of $(0.08) by 12.5%. However, the company's quarterly sales of $5.25M missed the analyst consensus estimate of $11.09M by 52.67%. This represents a significant decrease in both earnings and sales compared to the same period last year.
August 17, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Selecta Biosciences reported better than expected Q2 earnings per share but missed on sales. This mixed report could lead to uncertainty in the market.
While the company beat earnings per share estimates, the significant miss on sales could negatively impact investor sentiment. The mixed results create uncertainty about the company's performance and future outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100